Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — Investor Presentation (November 2020)
35 slides from Clearpoint Neuro's investor presentation, Nov 10, 2020
Slide 1: ClearPoint Neuro: When Your Path Is Clear, We Point the Way
CLEARPOINT NEURO WHEN YOUR PATH WE POINT THE WAY. November 2020
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Statements herein concerning ClearPoint Neuro, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance,
Slide 3: Severe Neurological Disorders Impact Millions of Patients and Families Each Year
Severe Neurological Disorders Impact Millions of Patients and Families Each Year Epilepsy Parkinson’s Disease of36 CLEARPOINT a w33° AADC Deficiency
Slide 4: Only a fraction of patients with debilitating neurological disorders are treated surgically
Only a fraction of patients with debilitating neurological disorders are being treated surgically today Prevalence of Neurological Disorders o 09 © © o © @ © © @ 9 9 @ @ 0 9 ©0 ©9 © @ © © © © © © @ © © 0 @ © © © @ 6 © © o @ © @ © © © © »@ © © © © © @ © © @ © @ © © © o 9 © © © © @ © © @ 9 © @ 9 o0 ©
Slide 5: The Movement to Minimally Invasive Procedures Has Happened Everywhere Else in the Body
The Movement to Minimally Invasive Procedures has Happened Everywhere Else in the Body This transition has always had two things in common * More patients being treated * Procedures enabled by live image guidance 53: CLEARPOINT © 2020 CLEARPOINT NEURO
Slide 6: Traditional Stereotactic Neurosurgery is Limited
Traditional Stereotactic Neurosurgery is Limited PRIMARY CHALLENGE The Skull is not ‘See Through’ X-Ray and CT do not show structures of the brain Large, Metallic Navigation Frames are not compatible inside an MRI Magnet Surgical Image Guidance in the Operating Room is not live but rather ‘Co-Regist
Slide 7: Our Solution — Procedure Overview
Our Solution — Procedure Overview ClearPoint® Neuro Navigation System Platform An MRI Compatible Navigation System Delivering Live MRI Guidance to the Procedure ENTRY PLANNING #3: CLEARPOINT © 2020 CLEARPOINT NEURO 7
Slide 8: Our Company: ClearPoint Neuro: A Proven Platform
Our Company ClearPoint Neuro: A Proven Platform Key Product HEADQUARTERS EMPLOYEES Irvine, CA 50+ 26+ field | 24+ production & development 2019 REVENUE* CASH °11.2m $14.7m" Razor / Razorblade model with 85+ % of 15% MARKET mn GROSS (ARcIN { revenue from single- Capital 5107m' 66% | use disposables a
Slide 9: ClearPoint Neuro: Two Companies in One
Our Company ClearPoint Neuro: Two Companies in One CLEARPOINT NEU A focus in Neurosurgery and unparalleled clinical support A Medical Device Company A Biologics & Drug Delivery Company ¢ $100M+ Existing Market, growing > 10% ¢ $1B+ Potential Market, first indication in 2021 ¢ Platform Navigation, Th
Slide 10: Broad and Growing User Base of Leading Neurosurgeons
Broad and Growing User Base of Leading Neurosurgeons Installed in 60 Top US Hospitals...and Expanding into the EU UC San Childret UCSF Benioff Chil San VA USC Keck UC San Diego Mayo Phoenix University of Colorado University of Utah University of Arizona Cook Children’s CLEARPOINT NEURO Cincinnati Ch
Slide 11: Our MRI-guided therapy platform is currently being used to...
Our MRI-guided therapy platform is currently being used to... Medtronic Medtronic PTC) SIEMENS ©eyager ise St. JUDE MEDICAL M fe) N T E R Il Ss THERAPEUTICS (36) weoient W Newrocrine Boston, Scientific qvovant rN face 1S 4 NERO ra IMRIS ENE ee CLEARPOINT © 2020 CLEARPOINT NEURO ..With 25 total partn
Slide 12: Capabilities
CAPABILITIES Our platform enables choice of precision-guided therapies and services CLEARPOINT NEURO Artificial Intelligence © 2020 CLEARPOINT NEURO
Slide 13: Example: The Parkinson's Disease Patient
CAPABILITIES Example: The Parkinson’s Disease Patient Enabling Surgeons to choose the right tool for the right patient © 2020 CLEARPOINT NEURO 13
Slide 14: Market Potential for Procedures
MARKET POTENTIAL FOR PROCEDURES GLOBAL SCALE Included Strategic & Focused Expansion to new geographies either direct or through partners Below Leverage existing sales channel for other distribution opp ities (i.e. CLS Laser Distributi Expansion and Leverage 50,000+ 20+ Current non-hospital partners
Slide 15: Market Opportunity
Market Opportunity 33% CLEARPOINT © 2020 CLEARPOINT NEURO
Slide 16: Deep Brain Stimulation
Deep Brain Stimulation ClearPoint® is used to accurately place leads in the appropriate targeted structure. The leads are connected in a separate procedure to a neurostimulator implanted near the collarbone. Deep brain stimulation (DBS) uses a surgically implanted medical device, similar to a cardia
Slide 17: 1. Neuro Navigation: Deep Brain Stimulation
1. Neuro Navigation Deep Brain Stimulation CLEARPOINT R INDUSTRY CHAN CeRnnne Medtronic HS) Abbott NELROPACE Parkinson’s Patient Population (US) Movement Disorders DBS Procedure Volumes Neuromodulation (Global): Currently 10% Annual Growth* Patients with * 12,500 implantations per Parkinson’s diseas
Slide 18: 1. Neuro Navigation: Deep Brain Stimulation
1. Neuro Navigation Deep Brain Stimulation CLEARPOINT MUST FACTOR INDUSTRY CHA Seana Medtronic GS) Abbott NELROPACE Parkinson’s Patient Population (US) 2019 Patients with 400 1.2M atients wi . oncon’s di implants Parkinson's disease 12,000 °», 6,000 are P ; , Implants/yr °° lead implants w 1M Patien
Slide 19: 2. Therapy: ClearPoint Neuro Laser Therapy
2. Therapy ClearPoint Neuro Laser Therapy LITT uses laser energy to destroy unwanted cells Laser Interstitial Thermal Therapy (LITT) is a minimally invasive surgical technique. A laser fiber is inserted through a tiny hole in the skull and then the laser applies energy to the targeted lesion, killin
Slide 20: ClearPoint Neuro's Right to Win in LITT
2. Therapy ClearPoint Neuro Laser Therapy ClearPoint Neuro’s Right to Win in LITT ClearPoint Neuro chosen by INFLEXION™ Head Fixation Frame TRANBERG® Laser ClearPoint® Compatibility Kits Neurosurgeons for the most difficult Neuro LITT cases today. One clinical support team and a simplified workflow
Slide 21: Significant Addressable Neuro Market in Epilepsy and Tumor
2. Therapy ClearPoint Neuro Laser Therapy Significant Addressable Neuro Market in Epilepsy and Tum Deepest, Smallest, Focal, Mesial Temporal Most Eloquent Epileptic Zone 15,000 * Initial beachhead market -> focal, MTLE cases and the most difficult brain tumor cases. Malignant Tumor 26,000 0. Tumor 6
Slide 22: The Current LITT Market is Small, but Strong Tailwinds Are in Place
2. Therapy ClearPoint Neuro Laser Therapy The Curre ITT Market is Small, but St Are in Place * Patients will continue to shift from open craniotomy to minimally invasive methods. Estimated US Neuro LITT Cases (4) US Neuro LITT Revenue 2500 $40,000,000 * Clinical evidence and payer $35,000,000 suppor
Slide 23: 3. Biologics & Drug Delivery: Pediatric Indications
3. Biologics & Drug Delivery Pediatric Indications Disorder AADC Deficiency Diffuse Intrinsic Pontine Glioma (DIPG) Friedreich’s Ataxia Description Rare (<1/1,000,000) autosomal recessive disorder caused by mutations in the DDC gene leading to significant deficiencies in dopamine and other neurotran
Slide 24: 3. Biologics & Drug Delivery: Pediatric Indications
3. Biologics & Drug Delivery Pediatric Indications Disorder Sanfilippo A (MPS IIIA) Tay-Sachs (GM2 idosis) Description Phase I/II Trial recessive, ive lysosomal storage disorder affecting 1/100,000 births. The primary disease characteristic is CNS degeneration which results in hyperactivity and ment
Slide 25: 3. Biologics & Drug Delivery: Adult Indications
3. Biologics & Drug Delivery Adult Indications Disorder Glioblastoma Parkinson's Disease Huntington’s Disease Amyotrophic Lateral Sclerosis (ALs) eferences: |. Mayo Clinic https://www.mayoctinic.0 causes/syc-20376055 4, Mayo Clinic https rg/cis li Description Non-Clinical One of the most common and
Slide 26: Patient Treatment Opportunity/Year
PATIENT TREATMENT OPPORTUNITY/YEAR 3. Biologics & Drug Delivery Estimated $1.5B* Market Opportunity As Platform for Gene Therapy 1,000 AADC Deficiency syndrome: Rare autosomal recessive disorder caused by mutations in the DDC gene leading to significant deficiencies in dopamine and other neurotransm
Slide 27: Patient Treatment Opportunity/Year
PATIENT TREATMENT OPPORTUNITY/YEAR 3. Biologics & Drug Delivery Estimated $1.5B* Market Opportunity As Platform for Gene Therapy 100,000 10,000 5,000 1,000 500 AADC Deficiency ~$12M! Sanfilippo Syndrome: Autosomal recessive, neurodegenerative lysosomal storage disorder affecting 1/100,000 births. Th
Slide 28: Patient Treatment Opportunity/Year
PATIENT TREATMENT OPPORTUNITY/YEAR 3. Biologics & Drug Delivery Estimated $1.5B* Market Opportunity As Platform for Gene Therapy 100,000 10,000 5,000 1,000 500 AADC Deficiency ~$12M! Sanfilippo Syndrome C ) ~$5M? Friedreich's Ataxia ~$60M" MPS IIIA Friedreich’s Ataxia: A genetic, progressive, neurod
Slide 29: Patient Treatment Opportunity/Year
PATIENT TREATMENT OPPORTUNITY/YEAR 3. Biologics & Drug Delivery Estimated $1.5B* Market Opportunity As Platform for | 200,000 100,000 10,000 5,000 1,000 Parkinson’s Disease ~$1.2B3 Huntington Disease ~$120M? Angelman oe Syndrome Friedreich's ~$72M! Ataxia $60M? e@ AADC Deficiency 712Mi MPS IIIA Sanf
Slide 30: 4. Global Scale
4. Global Scale Achieve Global Scale and Progress Toward Profitability Established Sales Channel capable of distributing other surgical products * Current Revenue for non-neuro CLS Laser Applicators Manufacturing Facility in Irvine capable of producing 5x current demand with existing footprint CE Ma
Slide 31: mlatelatelfslis
mlatelatelfslis
Slide 32: Growth in Case Volume and Revenue
Growth in Case Volume and Revenue Capital & Service $1,662 Disposables __™ Biologics and Drug Delivery Case Volume Growth 2013-2019 629 32.7% CAGR $980 $71 $1,097 egaen $3,908 fy 95.233 $5,313 $6,884 $ Thousands 2015 2016 2017 2018 267 } L 2013 2014 2015 2016 2017 2018 © 2020 CLEARPOINT NEURO ee CLE
Slide 33: Cash Flow From Operations
2015 - 2019 Cash Flow From Operations $(8,637) 2016 $(5,819) 2017 $(5,993) 2018 $(4,638) 2019 $(2,850) CASH AT September 30, 2020 $14.7 million ee CLEARPOINT
Slide 34: Executive Summary
CLPT CAPABILITIES Executive Summary Unique Platform technology ES enabling Precision MRI-Guided Therapies SAX to restore quality of life for some of the most debilitating disorders Large, Growing installed base in 60 of 250+ leading Neurology centers in U.S. 5O Procedure volume has grown 0 (| | 33%+
Slide 35: ClearPoint Neuro
CLEARPOINT NEURO ASQ WY \ \\\\ XX \\ «\ \ XK AN \ ‘a \\\) |
ClearPoint Neuro — Investor Presentation (November 2020) on 6ix